<DOC>
	<DOCNO>NCT02836704</DOCNO>
	<brief_summary>Primary Objective : -To test hypothesis high initial dose basal insulin ( 0.3 U/kg ) non inferior standard initial dose ( 0.2 U/kg ) base percentage patient least one episode hypoglycemia ( ≤3.9 mmol/L severe ) 16 week treatment overweight obese type 2 diabetic patient uncontrolled oral anti-diabetes drug ( OADs ) . Secondary Objective : - To evaluate percentage patient achieve glycated hemoglobin ( HbA1c ) &lt; 7 % . - To evaluate percentage accumulate percentage patient achieve fast plasma glucose ( FPG ) target ( &lt; 5.6 , &lt; 6.1 , &lt; 7.0 mmol/L ) . - To assess change HbA1c , FPG , postprandial glucose ( PPG ) . - To evaluate insulin dos change . - To evaluate weight change . - To evaluate overall hypoglycemia , nocturnal hypoglycemia severe hypoglycemia occurrence . - To descriptively evaluate safety profile . - To assess patient physician satisfaction adherence ( drop-out rate percentage patient follow treatment insulin titration ) . - Subgroup analysis efficacy ( control rate , control rate without confirm hypoglycemia , change HbA1c , FPG PPG ) safety data accord : - Age - Duration diabetes - Baseline treatment ( OAD ) - Baseline HbA1c , FPG PP</brief_summary>
	<brief_title>Comparison Standard v Higher Starting Dose Insulin Glargine Chinese Patients With Type 2 Diabetes ( Glargine Starting Dose )</brief_title>
	<detailed_description>The duration study patient approximately 20 week screen visit end-of-study follow-up phone call .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Age ≥ 18 ≤ 70 year . Type 2 diabetes patient diabetes diagnosis least 2 year . Continuous treatment stable dose 23 OADs , three month prior randomization , among metformin ≥1.5 g/day maximum tolerate dose HbA1c &gt; 7.5 % ≤11 % . FPG &gt; 9 mmol/L . BMI ≥25 ≤40 kg/m^2 . Ability willingness perform selfmonitoring blood glucose use Sponsorprovided glucose meter complete patient diary . Willingness ability comply study protocol . Signed informed consent obtain prior study procedure . Exclusion criterion : Known hypersensitivity/intolerance insulin glargine excipients . History hypoglycemia unawareness . Unexplained hypoglycemia past 6 month . Pregnancy plan pregnancy current lactation ( woman childbearing potential must negative pregnancy test study entry medically approve contraception method ) . Acute diabetic complication ( diabetic ketoacidosis , lactic acidosis , hyperosmolar nonketotic diabetic coma ) . History stroke , myocardial infarction , angina pectoris , coronary artery bypass graft , percutaneous transluminal coronary angioplasty within previous 12 month . Active proliferative retinopathy , define photocoagulation vitrectomy occurrence 6 month prior study entry , unstable ( rapidly progress ) retinopathy may require photocoagulation surgical treatment study , document retina examination disease history record , 2 year prior study entry . Impaired renal function define , limited , serum creatinine level ≥1.5 mg/dL ( 132 μmol/L ) males ≥1.4 mg/dL ( 123 μmol/L ) females presence macroproteinuria ( &gt; 2 g/day ) . Active liver disease ( alanine transaminase [ ALT ] great two time upper limit reference range , define local laboratory ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>